Table 3. Change in Functional Assessment of Cancer Therapy-Lung (FACT-L) score from baseline.

Scores on quality-of-life measures	Mean				At 12 weeks
	Docetaxel + bevacizumab [95% CI]	Pemetrexed + bevacizumab [95% CI]	P value*		Docetaxel + bevacizumab [95% CI]	Pemetrexed + bevacizumab [95% CI]	P value*
FACT-L (total)	−9.0 [−14.3, −3.6]	−3.1 [−7.7, 1.6]	0.097		−11.2 [−17.7, −4.7]	−1.5 [−7.5, 4.5]	0.037
FACT-L (TOI)	−8.4 [−12.3, −4.4]	−3.5 [−7.1, 0.2]	0.070		−10.3 [−15.0, −5.6]	−2.2 [−6.9, 2.5]	0.021
Subscale
Physical well-being	−2.3 [−3.8, −0.8]	−0.9 [−2.6, 0.8]	0.214		−2.7 [−4.1, −1.3]	−0.1 [−2.1, 1.9]	0.038
Social and family well-being	−0.9 [−2.4, 0.6]	−0.9 [−2.6, 0.8]	0.991		−1.5 [−3.3, 0.3]	−1.4 [−3.7, 0.9]	0.967
Emotional well-being	0.4 [−0.6, 1.4]	1.4 [0.3, 2.4]	0.181		0.4 [−0.8, 1.6]	2.1 [0.6, 3.6]	0.102
Functional well-being	−2.6 [−4.4, −0.8]	−1.3 [−3.6, 1.0]	0.355		−3.6 [−6.1, −1.1]	−1.1 [−3.3, 1.1]	0.150
Lung cancer	−3.8 [−5.5, −2.1]	−1.0 [−2.6, 0.6]	0.016		−4.6 [−6.6, −2.6]	−1.0 [−2.8, 0.9]	0.011

TOI, Trial Outcome Index; 95% CI, 95% confidential interval. *, Student’s t-test.